Answers are grounded in this paper and cite their sources.
Structural analysis demonstrates how dupilumab disrupts interleukin-4 receptor binding in atopic dermatitis, highlighting the molecular mechanisms of targeted monoclonal antibody therapies.
Learning Objectives Explain how monoclonal antibodies can be used as therapeutic agents to treat disease. Describe the molecular mechanism by which an antibody inhibitor disrupts interleukin signaling pathways. Analyze the three-dimensional structures of IL-4 bound to the IL-4 receptor and dupilumab bound to the IL-4 receptor. Identify and compare the intermolecular forces involved in IL-4–IL-4 receptor interactions versus dupilumab–IL-4 receptor interactions.
No takes yet. Share an insight, caveat, or question.
Youngjoo Kim (2026) studied this question.